<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003941</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-30974</org_study_id>
    <secondary_id>EORTC-30974</secondary_id>
    <nct_id>NCT00003941</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
      Peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy and&#xD;
      kill more cancer cells. It is not yet known whether chemotherapy and peripheral stem cell&#xD;
      transplant is more effective than chemotherapy alone.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying how well combination chemotherapy works&#xD;
      when given with peripheral stem cell transplant and how it compares with combination&#xD;
      chemotherapy alone in treating men with previously untreated germ cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of standard cisplatin, etoposide, and ifosfamide (VIP) followed by&#xD;
           sequential high-dose VIP and stem cell rescue versus bleomycin, etoposide, and cisplatin&#xD;
           (BEP) in men with previously untreated poor-prognosis germ cell cancer.&#xD;
&#xD;
        -  Compare the acute and late toxicities of these treatment regimens in this patient&#xD;
           population.&#xD;
&#xD;
        -  Compare these regimens in terms of failure-free survival, response rate, and overall&#xD;
           survival in these patients.&#xD;
&#xD;
        -  Evaluate the quality of life in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, primary mediastinal germ cell tumor (yes vs no), and nonpulmonary visceral metastases&#xD;
      (liver vs bone vs brain). Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive etoposide IV over 1 hour followed by cisplatin IV over 1 hour on&#xD;
           days 1-5 and bleomycin IV over 30 minutes on days 2, 8, and 15. Treatment repeats every&#xD;
           3 weeks for 4 courses.&#xD;
&#xD;
        -  Arm II: Patients receive 1 course of standard dose chemotherapy consisting of etoposide&#xD;
           IV over 1 hour followed by cisplatin IV over 1 hour and ifosfamide IV over 1 hour on&#xD;
           days 1-5. Peripheral blood stem cells (PBSC) are harvested around day 12-15. Patients&#xD;
           also receive daily filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing&#xD;
           until PBSC collection is complete.&#xD;
&#xD;
      After day 21, patients receive high-dose chemotherapy consisting of etoposide IV over 1 hour&#xD;
      followed by cisplatin IV over 1 hour, and ifosfamide IV over 1 hour on days -6 through -2.&#xD;
      PBSCs are infused on day 0. Patients receive daily G-CSF subcutaneously beginning on day 1&#xD;
      and continuing through day 19 or until blood counts have recovered. Treatment repeats every 3&#xD;
      weeks for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed before chemotherapy, at 6 months, and at 2 years after treatment.&#xD;
&#xD;
      Patients are followed monthly for 1 year, every 2 months for 1 year, every 3 months for 1&#xD;
      year, every 6 months for 1 year, and annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 222 patients (111 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival as measured by Logrank at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response as measured by negative tumor markers and no residual masses or viable cancer cells at the end of CT scan or debulking surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival as measured by Logrank at 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Quality of Life Questionnaire-Core 30 (QLQ-C30) v3.0 at baseline, at month 6, and at year 2</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by NCI-CTC v2.0 after each course, every 6 months up to year 5, and yearly</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Mediastinal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven germ cell cancer&#xD;
&#xD;
               -  Nonseminoma OR&#xD;
&#xD;
               -  Combined seminoma and nonseminoma&#xD;
&#xD;
          -  Poor prognosis (nonseminoma):&#xD;
&#xD;
               -  Testis/retroperitoneal primary AND&#xD;
&#xD;
               -  One of the following poor tumor markers&#xD;
&#xD;
                    -  AFP greater than 10,000 iu/L&#xD;
&#xD;
                    -  HCG greater than 50,000 iu/L&#xD;
&#xD;
                    -  LDH greater than 10 times upper limit of normal OR&#xD;
&#xD;
               -  Nonpulmonary visceral metastases (i.e., liver, bone, or brain) OR&#xD;
&#xD;
               -  Mediastinal primary&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 to 50&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min (unless due to obstructive uropathy&#xD;
             correctable by nephrostomy)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy except basal cell skin cancer&#xD;
&#xD;
          -  No neuropathy&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would prevent&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Concurrent radiotherapy for brain metastases allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Concurrent surgery for brain metastases allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gedske Daugaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig Boltzmann Institute for Applied Cancer Research at Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna (Wien)</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital - Aarhus Sygehus - Norrebrogade</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaft Krankenhaus</name>
      <address>
        <city>Bochum-Langendreer</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <zip>D-06822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital - Medical Klinik II</name>
      <address>
        <city>Duisburg</city>
        <zip>D-47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>DOH-06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich (Muenchen)</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Nord</name>
      <address>
        <city>Nuernberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02 781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario LA FE</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF4 7XL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011 May;22(5):1054-1061. doi: 10.1093/annonc/mdq575. Epub 2010 Nov 8.</citation>
    <PMID>21059637</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>mediastinal cancer</keyword>
  <keyword>testicular embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma</keyword>
  <keyword>testicular teratoma</keyword>
  <keyword>testicular yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma and teratoma</keyword>
  <keyword>testicular embryonal carcinoma and teratoma with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor</keyword>
  <keyword>testicular embryonal carcinoma and yolk sac tumor with seminoma</keyword>
  <keyword>testicular embryonal carcinoma and seminoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma</keyword>
  <keyword>testicular yolk sac tumor and teratoma with seminoma</keyword>
  <keyword>testicular choriocarcinoma and yolk sac tumor</keyword>
  <keyword>testicular choriocarcinoma and embryonal carcinoma</keyword>
  <keyword>testicular choriocarcinoma and teratoma</keyword>
  <keyword>testicular choriocarcinoma and seminoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>liver metastases</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Mediastinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

